



Robotic Automation for Cell Therapy Manufacturing


A Strategic Partnership between GenScript and Multiply Labs

GenScript Biotech Corporation and Multiply Labs have partnered to automate the cell isolation phase of cell therapy manufacturing. By combining GenScript's CytoSinct™ 1000 platform with Multiply Labs' automation expertise, the partnership aims to create a fully automated, customizable solution that reduces the complexity and high costs of cell therapy manufacturing.



This solution aims to mitigate the risk of human error throughout the end-to-end cell therapy manufacturing while simultaneously boosting cell therapy output and increasing access to cell therapy treatments for patients.

Side-by-side comparison of robotic vs. semi-automated cell isolation



In a Stanford and Multiply Labs study, CytoSinct™ 1000 demonstrated comparable T-cell purity and viability across fully-integrated robotic and non-integrated semi-automated cell enrichment and separation processes.

CytoSinct™ Cell Isolation Offerings (GMP)

Instruments	Standards
CytoSinct™ 1000	21 CFR Part 11 and ISO 13485 compliant
CytoSinct™ 1000 Tubing Set	
CytoSinct™ 1000 LS Tubing Set	
CytoSinct™ 1000 Depletion Tubing Set	

Reagents	Standards
CytoSinct™ CD4 Nanobeads, human	USP 1043 compliant
CytoSinct™ CD8 Nanobeads, human	
CytoSinct™ CD3 Nanobeads, human	
CytoSinct™ TCR αβ Nanobeads, human	
CytoSinct™ CD34 Nanobeads, human	
CytoSinct™ CD56 Nanobeads, human	
CytoSinct™ CD14 Nanobeads, human	
CytoSinct™ CD19 Nanobeads, human	

Cell Therapy Comprehensive Product Solutions

